Elevra Lithium Quarterly Activities Report
Elevra reported strong operational performance for the June 2026 quarter with record monthly spodumene production and 15% quarterly volume growth, though revenue dipped to $31 million due to a legacy contract with lagged pricing. The company successfully exited the legacy contract and finished the quarter with $255 million in cash and net cash of $200 million. The company finalized a Strategic Financing Package totaling over $300 million, combining a $196 million institutional placement and $102 million in convertible notes from Canada Growth Fund to fully fund its NAL Expansion.
Key figures
- Revenue
- 31
- Revenue Yoy
- 37%
- Deal Value Usd
- 71000000
- Net cash
- 200000000
- Cash balance
- 255000000
- Realised price
- 921
- Spodumene sales
- 33977
- Convertible notes
- US$102 million
- Nal expansion npv
- C$969 million
- Nal expansion capex
- C$366 million
- Share purchase plan
- US$11 million
- Unit operating cost
- 907
- Spodumene production
- 54479
- Institutional placement
- US$196 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.